Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000863894-23-000006
Filing Date
2023-05-11
Accepted
2023-05-11 15:38:32
Documents
76
Period of Report
2023-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q veru-20230331x10q.htm   iXBRL 10-Q 2842653
2 EX-31.1 veru-20230331xex31_1.htm EX-31.1 15657
3 EX-31.2 veru-20230331xex31_2.htm EX-31.2 15882
4 EX-32.1 veru-20230331xex32_1.htm EX-32.1 11606
  Complete submission text file 0000863894-23-000006.txt   11160854

Data Files

Seq Description Document Type Size
5 EX-101.SCH veru-20230331.xsd EX-101.SCH 61805
6 EX-101.CAL veru-20230331_cal.xml EX-101.CAL 72326
7 EX-101.DEF veru-20230331_def.xml EX-101.DEF 195228
8 EX-101.LAB veru-20230331_lab.xml EX-101.LAB 456410
9 EX-101.PRE veru-20230331_pre.xml EX-101.PRE 380388
70 EXTRACTED XBRL INSTANCE DOCUMENT veru-20230331x10q_htm.xml XML 2554365
Mailing Address 2916 N. MIAMI AVENUE SUITE 1000 MIAMI FL 33127
Business Address 2916 N. MIAMI AVENUE SUITE 1000 MIAMI FL 33127 3125959123
VERU INC. (Filer) CIK: 0000863894 (see all company filings)

EIN.: 391144397 | State of Incorp.: WI | Fiscal Year End: 0930
Type: 10-Q | Act: 34 | File No.: 001-13602 | Film No.: 23910636
SIC: 2834 Pharmaceutical Preparations